This weekly dosage helps ensure consistent levels of the medication in your body, providing continuous appetite suppression and support for weight loss
Currently, theres no evidence to suggest that drinking coffee interferes with this mechanism of action
Results: The 18-month risk for ION was 8.5 versus 5.5 per 10 000 among GLP-1RA users versus SGLT2i users (RD, 3.0 [95% CI, 0.4 to 5.7]) and 7.8 versus 4.2 per 10 000 among GLP-1RA users versus DPP4i users (RD, 3.6 [CI, 1.1 to 6.1])
If youre currently on tirzepatide or another GLP-1 medication like Ozempic or Wegovy (semaglutide) on Ro, your provider can help you determine when to stop, review safer alternatives, and create a plan to manage your weight or blood sugar before conception
G.JiaL.GuoL
STEP 1 and STEP-UP enrolled adults living with obesity, with slightly lower starting BMIs and different inclusion criteria